{"filings":[{"id":806240,"accession_number":"0001193125-26-253538","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2026-06-02T20:15:52+00:00","items":["5.02"],"status":"ready","headline":"Cytek Biosciences SVP Global Sales Philippe Busque resigns effective June 5","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Philippe Busque, Ph.D., SVP Global Sales and Services, resigned effective June 5, 2026.","Resignation is to pursue another career opportunity; not due to disagreement with company operations.","No successor or interim appointment announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95983,"accession_number":"0001193125-26-211948","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q1 revenue $44.1M (+6% YoY); net loss widens to $18.9M; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $44.1M (+6% YoY); service revenue $15.4M (+15%).","Installed base 3,789 instruments (+125 units); TTM recurring revenue 35% of total (up from 31%).","GAAP net loss $18.9M vs $11.4M; adjusted EBITDA loss $9.1M vs $3.3M loss.","G&A expenses up 43% YoY driven by litigation, consulting, and bad debt reserves.","Reaffirms FY2026 revenue guidance $205M-$212M (2-5% growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":44135000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109461,"accession_number":"0001193125-26-076768","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q4 revenue $62.1M (+8% YoY); net loss $44.1M on $38.1M deferred tax valuation allowance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 revenue $201.5M (+1% YoY); Q4 set record quarterly revenue.","GAAP gross margin 53% in Q4 vs 59% a year ago; adjusted gross margin 55% vs 61%.","Full-year net loss $66.5M vs $6.0M in 2024, driven by $33.1M non-cash deferred tax valuation allowance and higher expenses.","Adjusted EBITDA for 2025 was $5.0M, down from $22.4M; excluding investment income, was $(3.1)M.","Guides FY2026 revenue of $205-212M, representing 2-5% growth over 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":201493000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109460,"accession_number":"0001193125-26-011748","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek sees Q4 rev $62M (+8% YoY); FY2025 rev ~$201M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 revenue of ~$62M, up 8% YoY and 19% QoQ.","Full-year 2025 revenue estimated at ~$201M.","CEO cites strong Services, Reagents and APAC instrument growth; EMEA returns to positive instrument sales.","Company to present at JP Morgan Healthcare Conference on Jan 14, 2026.","Full Q4 and FY results with 2026 guidance expected late February 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":201493000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125965,"accession_number":"0001193125-25-266973","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q3 2025 net loss $5.5M; adjusted EBITDA $2.5M; revenue +2% to $52.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $52.3M, +2% YoY; installed base 3,456 instruments (+161 units in Q3).","GAAP net loss $5.5M vs net income $0.9M in Q3 2024; GAAP gross margin 53% vs 56%.","Adjusted EBITDA $2.5M vs $7.6M in prior year; ex-investment income $0.5M vs $5.7M.","Recurring revenue up 19% YoY; biopharma/CRO revenue up 14% YoY.","FY2025 revenue guidance reaffirmed $196M-$205M (-2% to +2% growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":139352000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142707,"accession_number":"0001193125-25-174459","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q2 2025 revenue $45.6M (-2% YoY); narrows 2025 guidance to $196-205M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $45.6M, down 2% YoY; net loss $5.6M vs $10.4M loss in Q2 2024.","Adjusted EBITDA $1.3M (down from $2.9M); operating loss $10.6M vs $8.5M.","Installed base grew to 3,295 instruments (146 new units); launched Aurora Evo system.","Recurring revenue up 16% YoY; repurchased $4.5M in stock during Q2.","2025 revenue guidance narrowed to $196-205M (flat to -2% growth over 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":87059000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160772,"accession_number":"0001193125-25-145725","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cytek director nominee Deborah Neff fails election; other proposals pass","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deborah Neff received 33.8M votes for vs. 48.2M withheld, failing to be elected as Class I director.","Richard Chin was re-elected with 81.8M votes for and 0.2M withheld.","Advisory say-on-pay proposal passed with 76.4M votes for (93.1% of votes cast excluding broker non-votes).","Ratification of Deloitte & Touche as auditor passed with 95.9M for (92.3% of votes cast).","Quorum of 81.4% of outstanding shares represented at the June 18, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160771,"accession_number":"0001193125-25-115965","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q1 revenue down 7.6% to $41.5M; net loss widens; FY2025 guidance reduced","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $41.5M (-7.6% YoY); gross margin 49% vs 51%; net loss $11.4M vs $6.2M loss prior year.","Adjusted EBITDA loss $3.3M vs $0.7M loss; cash & securities $265.6M, down $12.3M from Dec 2024.","FY2025 revenue guidance revised to $196-210M (-2% to +5% YoY); prior guidance withdrawn.","Repurchased $10.6M of common stock in Q1; launched Cytek Muse Micro instrument.","Strength in APAC and cell sorters/service business offset by US/EMEA product sales slowdown."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":41457000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178972,"accession_number":"0001193125-25-039225","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Biosciences Q4 rev $57.5M (-1.3%); FY24 net loss $6.0M; guides FY25 rev $204-212M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2024 revenue $200.5M (+3.9% YoY); Q4 revenue $57.5M (-1.3% YoY, +1.4% constant currency).","Net loss improved to $6.0M from $12.1M in 2023; adjusted EBITDA $22.4M (+77% YoY).","Installed base reached 3,034 instruments; 667 placed in 2024.","Board authorized new $50M stock repurchase program for 2025; $21.6M repurchased in 2024.","2025 revenue guidance $204-212M (2-6% growth); opened Singapore manufacturing facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":200453000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178971,"accession_number":"0001193125-25-006599","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Biosciences expects FY2024 revenue $200-201M, 4% growth; Q4 rev up 11-13% QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2024 revenue expected $200-201M, up 4% from $193M in 2023; ~$1M negative FX impact.","Q4 2024 revenue $57-58M, 11-13% sequential growth, down 2% to flat YoY; FX reduced Q4 by ~$1.5M.","CEO cites strong APAC and Rest of World growth, offset by order delays and USD strength.","Preliminary results unaudited; full earnings and 2025 guidance expected late February 2025.","Company to present at J.P. Morgan Healthcare Conference on January 16, 2025 in San Francisco."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":200453000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195657,"accession_number":"0001193125-24-251268","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q3 revenue $51.5M (+7% YoY); net income $0.9M vs loss year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $51.5M, up 7% vs Q3 2023; year-to-date revenue $143.0M, up 6%.","GAAP net income $0.9M vs net loss of $6.5M in Q3 2023; adjusted EBITDA $7.6M vs $3.7M.","Installed base expanded to 2,821 units, adding 164 units in Q3.","Repurchased $12.1M of stock during Q3; cash and securities $277.8M.","FY2024 revenue guidance reaffirmed at $203-210M, expecting positive operating cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":142977000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211920,"accession_number":"0001193125-24-217558","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cytek Biosciences COO Paul Christopher Williams resigns effective Sept 27, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Paul Christopher Williams resigned on Sept 9, 2024, effective Sept 27, 2024, to pursue another career opportunity.","No replacement has been named; CEO Wenbin Jiang remains in charge.","Resignation is voluntary and not due to any disagreement with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211919,"accession_number":"0001193125-24-194907","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q2 revenue $46.6M, -6% YoY; net loss widens to $10.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $46.6M (-6% YoY, +4% QoQ); GAAP gross margin 55% (adjusted 58%).","Net loss $10.4M vs $4.4M in Q2 2023; operating loss $8.5M vs $9.1M.","Adjusted EBITDA $2.9M vs $1.5M; cash and securities $277.2M.","FY2024 revenue guidance narrowed to $203-210M (5-9% growth); expects positive cash flow from ops.","Repurchased $2.7M of stock; total installed base 2,656 instruments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":91477000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230711,"accession_number":"0001193125-24-159094","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cytek Biosciences 2024 annual meeting results: all proposals approved by shareholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Wenbin Jiang and Michael Holder as Class III directors with 64.2M and 70.3M votes for, respectively.","Advisory vote on executive compensation approved: 63.5M for, 10.5M against, 78.9K abstentions.","Ratified Deloitte & Touche LLP as independent auditor for FY2024: 94.1M for, 2.3M against, 656.7K abstentions.","Approximately 74% of outstanding shares (97.1M of 131.3M) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230710,"accession_number":"0001193125-24-134238","cik":1831915,"company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytek Q1 revenue $44.9M (+21% YoY); organic revenue up 11%; reaffirms 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $44.9M, +21% YoY; organic revenue (ex-Luminex) $37.3M, +11%.","Gross profit margin 51% (down from 57%); adjusted gross margin 55% (down from 59%).","Net loss $6.2M vs $6.8M loss; Adjusted EBITDA loss $0.7M vs $2.5M loss.","Reaffirms 2024 revenue guidance $203M-$213M (5-10% growth); expects positive net income for FY2024.","Appointed William McCombe as CFO; opened new facility in Wuxi, China; received NMPA approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":44860000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":526256069.46741855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}